Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery

Journal of Anesthesia

Volumn 27, Issue 3, 2013, Pages 334-339

  Ebade, Abdelhay A ^a   Khalil, Mohamed A ^a,b   Mohamed, Ahmed K ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b SAAD SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

Congenital cardiac septal defects; Dobutamine; Levosimendan; Pulmonary hypertension

Indexed keywords

ATROPINE; DOBUTAMINE; FENTANYL; GLYCERYL TRINITRATE; HEPARIN; HYDROCORTISONE; LEVOSIMENDAN; MIDAZOLAM; PANCURONIUM BROMIDE; PHENYLEPHRINE;

ANESTHESIA INDUCTION; ARTICLE; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; FEMALE; HEART INDEX; HEART SEPTUM DEFECT; HEART SURGERY; HEMODYNAMICS; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INFANT; INTENSIVE CARE UNIT; INTRAOPERATIVE PERIOD; LUNG ARTERY; LUNG ARTERY PRESSURE; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

BLOOD PRESSURE; CARDIAC OUTPUT; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; CHILD, PRESCHOOL; DOBUTAMINE; FEMALE; HUMANS; HYDRAZONES; HYPERTENSION, PULMONARY; INFANT; MALE; PROSPECTIVE STUDIES; PULMONARY ARTERY; PYRIDAZINES;

EID: 84879227046     PISSN: 09138668     EISSN: 14388359     Source Type: Journal    
DOI: 10.1007/s00540-012-1537-9     Document Type: Article

References (29)

1. Hoffman JIE, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation. 1981;64:873-7.
2. Rabinovitch M, Bothwell T, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension; a correlation of light with scanning electron microscopy and transmission electron microscope. Lab Invest. 1986;55:632-53.
3. Landoni G, Mizzi A, Biondi-Zoccai G, Bignami E, Prati P, Ajello V, Marino G, Guarracino F, Zangrillo A. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol. 2010;76(4):276-86.
4. Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40(2):634-46.
5. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-7.
6. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Någren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during levosimendan infusion in congestive heart failure. J Clin Pharmacol Ther. 2000;68:522-31.
7. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Calcium sensitizer activates the glibenclamide-sensitive K channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249-59.
8. Lilleberg J, Nieminen MS, Akkila J, Heikkilä L, Kuitunen A, Lehtonen L, Verkkala K, Mattila S, Salmenperä M. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660-8.
9. Nieminen MS, Akkila J, Hasenfuss G. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;3:1903-12.
10. Revermann M, Schloss M, Mieth A, Babelova A, Schröder K, Neofitidou S, Buerkl J, Kirschning T, Schermuly RT, Hofstetter C, Brandes RP. Levosimendan attenuates pulmonary vascular remodeling. Intensive Care Med. 2011;37(8):1368-77.
11. Goodman Gilman A, Rall TW, Nies AS, Taylor P. Catecholamines and sympathomimetic drugs. In: Goodman and Gilman's the pharmacological basis of therapeutics, 8th edn. New York: Pergamon; 1990, p. 202-3.
12. Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail. 2003;5:101-8.
13. Tibby SM, Hatherill M, Durward A, Murdoch IA. Are transoesophageal Doppler parameters a reliable guide to pediatric hemodynamic status and fluid management? Intensive Care Med. 2001;27(1):201-5.
14. Lomivorotov VV, Boboshko VA, Efremov SM, Kornilov IA, Chernyavskiy AM, Lomivorotov VN, Knazkova LG, Karaskov AM. Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients. J Cardiothorac Vasc Anesth. 2012;26(4):596-603.
15. Lomivorotov VV, Cherniavskiy AM, Boboshko VA, Kornilov IA, Lomivorotov VN, Karaskov AM. Levosimendan versus intra-aortic balloon pump in high-risk cardiac surgery. Asian Cardiovasc Thorac Ann. 2011;19(2):154-9.
16. Lahtinen P, Pitkänen O, Pölönen P, Turpeinen A, Kiviniemi V, Uusaro A. Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Crit Care Med. 2011;39(10):2263-70.
17. Momeni M, Rubay J, Matta A, Rennotte M-T, et al. Levosimendan in congenital cardiac surgery: a randomized double-blind clinical trial. J Cardiothorac Vasc Anesth. 2011;25(3):419-24.
18. Braun J-P, Schneider M, Dohmen P, Döpfmer U. Successful treatment of dilated cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support. J Cardiothorac Vasc Anesth. 2004;18(6):772-4.
19. Lobacheva GV, Khar'kin AV, Manerova AF, Dzhobava ER. Intensive care for newborns and babies of the first year of life with acute heart failure after cardiosurgical interventions. Anesteziol Reanimatol. 2010;5:23-7.
20. Malliotakis P, Xenikakis T, Linardakis M, Hassoulas J. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series. Hellenic J Cardiol. 2007;48(2):80-8.
21. Buerkem B, Lemm H, Krohe K, Dietz S, Raaz U, Buerke U, Russ M, Schlitt A, Werdan K. Levosimendan in the treatment of cardiogenic shock. Minerva Cardioangiol. 2010;58(4):519-30.
22. Eremenko AA, Kolpakov PE, Babaev MA, Revunenkov GV, Fominykh MV. Use of levosimendan in cardiosurgical patients with chronic heart insufficiency. Anesteziol Reanimatol. 2010;2:24-6.
23. Ouanes-Besbes L, Ouanes I, Dachraoui F, Dimassi S, Mebazaa A, Abroug F. Weaning difficult-to-wean chronic obstructive pulmonary disease patients: a pilot study comparing initial hemodynamic effects of levosimendan and dobutamine. J Crit Care. 2011;26(1):15-21.
24. Mandal B, Kapoor PM, Chowdhury U, Kiran U, Choudhury M. Acute hemodynamic effects of inhaled nitroglycerine, intravenous nitroglycerine, and their combination with intravenous dobutamine in patients with secondary pulmonary hypertension. Ann Card Anaesth. 2010;13(2):138-44.
25. Torres J, Delgado JF, Sanz J, Gonzalez A, Sanchez V, Gamez S, Escribano P, Saenz C. Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients. Transpl Proc. 2009;41(6):2477-9.
26. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med. 2007;35(9):2037-50.
27. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K, Lehtonen L, Pulkki LM. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther. 1997;61:596-607.
28. Harkin CP, Pagel PS, Tessmer JP, Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol. 1995;26:179-88.
29. Talwar S, Choudhary SK, Garg S, Saxena A, Ramakrishnan S, Kothari SS, Juneja R, Airan B. Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension. Interact Cardiovasc Thorac Surg. 2012;14:699-703.